By Patrick Wingrove

(Reuters) -Novo Nordisk said on Monday it has begun selling its popular weight-loss drug Wegovy for $349 a month to cash payers, months ahead of the timeline set out with the Trump administration.

The same cash price will apply to most doses of Novo’s diabetes drug Ozempic, the company said, except the highest 2 mg dose, which will remain $499.

Novo and U.S. President Donald Trump announced a deal earlier this month to cut the prices of Wegovy and Ozempic, both known chemically as semaglutide, to $350 a month for cash payers starting in January, down from $499.

U.S. rival Eli Lilly also announced that the lowest dose of its obesity medicine Zepbound would be available for $299 per month as of January, with additional doses priced at $449 per month for cash-paying pa

See Full Page